Finance entity

Ameluz

Product

earnings is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention Biofrontera Inc., the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.7 for the same window.

Last mentioned: Mar 19, 2026

Entity pulse

Recent coverage · Ameluz

2 stories
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Ameluz

earnings is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention Biofrontera Inc., the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.7 for the same window. Their average consequence score of 5 runs below the beat's 6.4 for that window. Ameluz appears in 2 tracked Finance stories from March 19, 2026.

Stories tracked
2
Sources per story
2

Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 105 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Ameluz. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Ameluz 2

Earnings Neutral

Biofrontera and DarioHealth Pivot Toward Profitability in Q4 2025 Results

Biofrontera and DarioHealth reported Q4 2025 results on March 19, 2026, highlighting a strategic shift from aggressive growth to sustainable profitability. While Biofrontera focuses on expanding its dermatology market share with Ameluz, DarioHealth is leveraging its B2B2C model to drive high-margin digital health revenue.

2 sources
Earnings Neutral

Armanino Foods and Biofrontera Report Record 2025 Earnings

Armanino Foods and Biofrontera Inc. both reported record-breaking fourth-quarter and full-year 2025 financial results on March 19, 2026. These reports highlight strong execution in the specialty food and dermatological pharmaceutical sectors, respectively.

2 sources

Ameluz is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.